Find Clinical Trials

Recruiting

Novel Treatment for Type 2 Diabetes

Mayo Clinic

Phase Phase 3
Study Type Interventional
Participants 500
Duration 12 months

This study evaluates the efficacy and safety of a new oral medication for managing blood glucose levels in adults with type 2 diabetes who have not achieved adequate control with current treatments.

View Details
Recruiting

Immunotherapy for Advanced Melanoma

MD Anderson Cancer Center

Phase Phase 2
Study Type Interventional
Participants 120
Duration 24 months

This trial investigates a combination immunotherapy approach for patients with advanced melanoma who have not responded to standard treatments, with the goal of improving survival rates.

View Details
Active

Gene Therapy for Parkinson's Disease

Johns Hopkins Medicine

Phase Phase 1/2
Study Type Interventional
Participants 45
Duration 36 months

This study evaluates a novel gene therapy approach that aims to slow or halt the progression of Parkinson's disease by delivering therapeutic genes to specific regions of the brain.

View Details
Recruiting

Stem Cell Therapy for Heart Failure

Cleveland Clinic

Phase Phase 2
Study Type Interventional
Participants 80
Duration 18 months

This trial investigates the use of autologous stem cells to repair damaged heart tissue in patients with heart failure, potentially improving cardiac function and quality of life.

View Details
Completed

Novel Drug for Alzheimer's Disease

Massachusetts General Hospital

Phase Phase 3
Study Type Interventional
Participants 350
Duration 24 months

This completed study evaluated a new drug targeting amyloid plaques in the brain, showing promising results in slowing cognitive decline in patients with early-stage Alzheimer's disease.

View Results
Recruiting

Biologic Treatment for Multiple Sclerosis

Stanford Medicine

Phase Phase 2/3
Study Type Interventional
Participants 220
Duration 30 months

This study evaluates a new biologic therapy that targets specific immune cells involved in the progression of multiple sclerosis, potentially reducing relapses and disability progression.

View Details